{"title":"火灾(发热感染伴难治性癫痫综合征)患儿服用氯巴扎明引起皮疹的罕见不良反应","authors":"Saheli Das, Afshan Jabeen","doi":"10.22159/ajpcr.2024v17i7.51071","DOIUrl":null,"url":null,"abstract":"Clobazam, an aromatic antiepileptic drugs and its active metabolite desmethylclobazam, has high affinity and agonistic activity on gamma-aminobutyric acid receptors resulting in suppression of abnormal and excessive activity of neurons. The reported incidence of maculopapular rash with Clobazam is <1%. A 13-year-old male with a diagnosis of febrile infection-related epilepsy syndrome developed a generalized erythematous maculopapular rash the next day following the introduction of Clobazam. Following this event, Clobazam was stopped and reintroduced after 17 days. However, the rash did not appear after its reintroduction. It was observed that the patient was on Fluconazole when the rash appeared. Fluconazole being a strong CYP2C19 inhibitor, results in an increased level of active metabolite, desmethylclobazam, which probably could have caused the rash. According to the World Health Organization, Uppsala Monitoring Centre Criteria, causality assessment was found to be probable. Adverse drug reaction was recorded and reported.","PeriodicalId":8528,"journal":{"name":"Asian Journal of Pharmaceutical and Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A RARE ADVERSE EFFECT OF CLOBAZAM INDUCED RASH IN A CHILD WITH FIRES (FEBRILE INFECTION WITH REFRACTORY EPILEPSY SYNDROME)\",\"authors\":\"Saheli Das, Afshan Jabeen\",\"doi\":\"10.22159/ajpcr.2024v17i7.51071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clobazam, an aromatic antiepileptic drugs and its active metabolite desmethylclobazam, has high affinity and agonistic activity on gamma-aminobutyric acid receptors resulting in suppression of abnormal and excessive activity of neurons. The reported incidence of maculopapular rash with Clobazam is <1%. A 13-year-old male with a diagnosis of febrile infection-related epilepsy syndrome developed a generalized erythematous maculopapular rash the next day following the introduction of Clobazam. Following this event, Clobazam was stopped and reintroduced after 17 days. However, the rash did not appear after its reintroduction. It was observed that the patient was on Fluconazole when the rash appeared. Fluconazole being a strong CYP2C19 inhibitor, results in an increased level of active metabolite, desmethylclobazam, which probably could have caused the rash. According to the World Health Organization, Uppsala Monitoring Centre Criteria, causality assessment was found to be probable. Adverse drug reaction was recorded and reported.\",\"PeriodicalId\":8528,\"journal\":{\"name\":\"Asian Journal of Pharmaceutical and Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Journal of Pharmaceutical and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22159/ajpcr.2024v17i7.51071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ajpcr.2024v17i7.51071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A RARE ADVERSE EFFECT OF CLOBAZAM INDUCED RASH IN A CHILD WITH FIRES (FEBRILE INFECTION WITH REFRACTORY EPILEPSY SYNDROME)
Clobazam, an aromatic antiepileptic drugs and its active metabolite desmethylclobazam, has high affinity and agonistic activity on gamma-aminobutyric acid receptors resulting in suppression of abnormal and excessive activity of neurons. The reported incidence of maculopapular rash with Clobazam is <1%. A 13-year-old male with a diagnosis of febrile infection-related epilepsy syndrome developed a generalized erythematous maculopapular rash the next day following the introduction of Clobazam. Following this event, Clobazam was stopped and reintroduced after 17 days. However, the rash did not appear after its reintroduction. It was observed that the patient was on Fluconazole when the rash appeared. Fluconazole being a strong CYP2C19 inhibitor, results in an increased level of active metabolite, desmethylclobazam, which probably could have caused the rash. According to the World Health Organization, Uppsala Monitoring Centre Criteria, causality assessment was found to be probable. Adverse drug reaction was recorded and reported.